Towards Equitable Genomics: Rethinking the Genetic Architecture of Multiple Sclerosis
The article, “Towards a global view of multiple sclerosis genetics,” argues that multiple sclerosis (MS) genetics has reached an important methodological and ethical turning point. Although MS is a neuroimmunological disorder with a substantial heritable component, most genetic knowledge about MS susceptibility has been derived from populations of European ancestry. This is problematic because people of European ancestry represent only a minority of the global population, yet they constitute the overwhelming majority of participants in genome-wide association studies. In MS specifically, European-ancestry GWAS have identified 32 independent signals in the major histocompatibility complex, 200 additional autosomal loci, and one X-chromosome locus, collectively explaining up to approximately half of estimated MS heritability; however, these findings cannot automatically be assumed to describe MS risk in all ancestral groups.
Diversity as a Scientific Requirement, Not Only an Ethical Obligation
The authors emphasize that inclusion of non-European populations in MS genetics is not merely a question of fairness, although the ethical case is strong. If genomic medicine, polygenic risk scores, pharmacogenetics, or genetically informed prognosis become part of routine MS care, under-represented populations may receive less accurate or inferior clinical benefit. The article therefore frames ancestry diversity as a scientific necessity: without multi-ancestry data, researchers cannot reliably determine which genetic associations are universal, which are population-specific, and which are artifacts of linkage disequilibrium patterns observed mainly in European cohorts.
Genetics and the Global Epidemiology of MS
A central theme of the article is that cross-ancestral genetics could help explain striking global differences in MS prevalence and incidence. The authors cite Global Burden of Disease estimates showing large geographic variation, from very low age-standardized prevalence in regions such as Oceania and central sub-Saharan Africa to much higher prevalence in high-income North America. They also note that environmental factors, diagnostic access, ascertainment bias, migration, smoking, obesity, vitamin D exposure, and health-care infrastructure all complicate interpretation. A pan-ancestral genetic map of MS could help separate genetic contributions from social, clinical, and environmental determinants, and might even help estimate hidden disease burden in low-resource settings where neurological diagnosis is limited.
The MHC Locus and the Importance of HLA Variation
The major histocompatibility complex remains the strongest genetic region associated with MS, but its interpretation is particularly complex because of dense immune-related genes, long-range haplotypes, and ancestry-specific linkage disequilibrium. The article highlights HLA-DRB115:01 as a major MS risk allele in European populations, while also explaining that HLA allele frequencies vary widely across populations. The map in Figure 1 illustrates global variation in HLA-DRB115:01 allele frequency, showing that the allele is relatively common in parts of Europe and North America but rarer in Africa and South Asia. This variation creates an opportunity: by studying populations with different haplotypic structures, researchers can better identify which HLA alleles are truly causal and which are merely correlated with causal variants.
Beyond the MHC: Shared Architecture and Population-Specific Signals
Outside the MHC, the article reports that many large-effect MS risk alleles identified in European populations appear to have broadly similar effects in African American, Hispanic, Sardinian, Greek, South Asian, and Japanese cohorts. Nevertheless, detecting true heterogeneity across ancestries is statistically difficult because marginal effects can differ simply because of allele-frequency and linkage-disequilibrium differences. The authors discuss intriguing examples, including variants near MALT1 and PTGER4, where effect-size differences have been observed among Hispanic, African American, and European-ancestry populations. These findings require larger studies, but they suggest that multi-ancestry MS genetics may reveal biologically meaningful differences in immune regulation, vitamin D signaling, and other disease-relevant pathways.
Fine Mapping, Risk Prediction, and Mechanistic Discovery
The article’s strongest scientific argument is that cross-ancestral studies can sharpen causal inference. Variants discovered by GWAS are often not causal themselves; rather, they tag causal variants through linkage disequilibrium. Because linkage disequilibrium blocks are often shorter in populations of African ancestry, multi-ancestry GWAS can narrow credible sets and improve fine mapping. Figure 2 illustrates this principle by showing how association peaks differ between African- and European-ancestry populations and how combining them can reduce the genomic interval likely to contain the causal variant. The article also notes that polygenic risk scores trained mainly in European populations perform poorly in non-European populations, meaning that clinically useful MS risk prediction will require substantially larger non-European GWAS datasets.
Challenges and the Path Toward Equitable MS Genomics
The authors conclude that the major barriers to global MS genetics are substantial but not insurmountable. These include cost, limited sample sizes, difficulty recruiting appropriate controls, population stratification, underpowered GWAS in low-prevalence settings, and the historical design of genotyping arrays around European linkage patterns. They also stress that ethical practice is inseparable from good science: research in non-European populations must involve local researchers, build durable infrastructure, avoid discriminatory interpretation, and include participants in study design and communication. The article ultimately argues for consortium-scale, ethically grounded, multi-ancestry MS genetics as a route to better biology, better prediction, and more equitable clinical translation for all people with MS.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Jacobs, B.M., Peter, M., Giovannoni, G. et al. Towards a global view of multiple sclerosis genetics. Nat Rev Neurol 18, 613–623 (2022). https://doi.org/10.1038/s41582-022-00704-y
